ETON PHARMACEUTICALS INC
ETONNASDAQTrading Snapshot
- Day Range
- β
- 52-Week Range
- $14.27 β $66.37
- Volume (shares)
- β
- Avg Volume (shares)
- β
- Shares Outstanding
- 28.6M
- Next Earnings
- 2026-11-05
Fundamentals Snapshot
- Annual Revenue
- $80M
- Last Q Revenue
- $38M
- P/E Ratio
- 115.1
- P/S Ratio
- 13.8x
- EPS (TTM)
- $0.39
- Dividend Yield
- β
- Dilution (1yr)
- +3.0%
ETON PHARMACEUTICALS INC
ETONAbout ETON PHARMACEUTICALS INC
Eton Pharmaceuticals, Inc., a pharmaceutical company, focuses on developing and commercializing treatments for rare diseases. Its commercial rare disease products include Increlex for the treatment of severe primary igf-1 deficiency; Alkindi Sprinkle for adrenal insufficiency; Khindivi for adrenocortical insufficiency; Galzin for Wilson disease; PKU Golike for phenylketonuria; Carglumic Acid for N-acetylglutamate synthase deficiency; Betaine Anhydrous for homocystinuria; and Nitisinone for tyrosinemia type 1. The company is also developing various product candidates, which are in late-stage development, including ET-600 for diabetes insipidus; Amglidia for neonatal diabetes mellitus; ET-700 for Wilson disease; ET-800 for adrenal insufficiency; and ZENEO hydrocortisone autoinjector for adrenal crisis. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.
Otter Score Breakdown
How it's scoredFive components, each rated 1β5β and equally weighted (20%), averaged to a 0β100 score:π Quality β gross marginπ Growth β revenue YoYβοΈ Valuation β P/S ratioβ‘ Momentum β 30-day price changeπ§ Dilution β 1-yr share issuance (buybacks score higher)Latest News & Updates
News unavailable.